At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 502 enrolled
Drug / intervention
telmisartan/amlodipinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-label TElmisartan/AMlodipine Single Pill STudy to Assess the Efficacy in Patients With Essential Hypertension"..."
In Brief
A Phase 3 clinical trial evaluating telmisartan/amlodipine for Hypertension. Completed, enrolled 502 participants across 47 sites in 5 countries.
Detailed Summary
The general aim of this trial to determine the efficacy as measured by the percentage of patients reaching blood pressure goal at the end of the treatment period at 12 weeks. In-clinic blood pressures, home blood pressures and safety will be carefully monitored.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesGermany, Italy, Mexico, Netherlands, Poland
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedJun 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedJun 2, 2010
Enrollment StartMay 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.1 years ago
Interventions
telmisartan/amlodipinedrug
start low dose and uptitrate to high dose on the basis of BP goal